Denver, Colorado – iSpecimen (NASDAQ:ISPC) is making a significant operational leap, announcing a revamped logistics model that dramatically reduces the time it takes to deliver human biospecimens to researchers worldwide.
The company, which operates an online marketplace connecting researchers with biospecimen providers, has shifted away from a centralized shipping model to a more direct, supplier-to-customer approach. The result is a faster, more efficient supply chain designed to meet the time-sensitive demands of modern scientific research.
Previously, biospecimens often passed through centralized processing hubs before reaching their final destination, a step that could add anywhere from 7 to 14 days to delivery timelines. Under the new system, those delays are largely eliminated. Domestic shipments can now arrive in as little as one to two days, representing a reduction in transit times of approximately 70% to 85%.
Beyond speed, the streamlined process also reduces costs by minimizing handling points and simplifying logistics. The company has supported this transition with expanded training and tighter operational coordination across its growing global supplier network.
Internationally, iSpecimen is also strengthening its reach. By expanding partnerships with sourcing organizations across Europe and Eastern Europe, the company is improving access to rare and hard-to-source biospecimens, an important factor for specialized and high-stakes research. Combined with the direct shipping model, these enhancements are helping deliver more consistent turnaround times for global customers.
Early feedback suggests the changes are resonating. Customers have reported improvements not only in delivery speed but also in reliability and overall quality of service, particularly for sensitive and time-critical materials.
CEO Katie Field stated, “Since this process improvement customers have been pleased too, for example one was ‘impressed with the quality and care taken…in the careful sourcing and handling of the research materials.’ We are proud that our customers use rare materials that we source to advance scientific research.”
As demand for precision medicine, clinical research, and biotech innovation continues to rise, faster access to high-quality biospecimens could become a competitive differentiator. With this logistics overhaul, iSpecimen is positioning itself as a more agile and responsive partner in the global research ecosystem.
Source: https://api.quotemedia.com/supplement/news-story/?webmasterId=102353&storyId=8928540463278579